HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CBD News Round-Up: Australia Proposes OTC Pathway, First EU Novel Food Validation, COVID Boost For UK Firm

Executive Summary

Australia looks at switching CBD as an OTC medicine, CBDepot becomes the first European firm with an EU Novel Food validation and the UK's Vitality CBD gets a boost from the global, coronavirus-driven wellness trend. 

You may also be interested in...



Australia Continues Down OTC Path For CBD, But Will It Widen Access?

[Link Fixed] Australia's Ministry of Health has provisionally switched CBD from prescription-only to OTC status to widen access in the absence of any safety concerns and to encourage companies to undertake much-needed clinical trials to prove efficacy for CBD in low doses. However, switch expert Natalie Gauld thinks these expensive trials, and therefore approved Australian OTC CBD products, may not be forthcoming.

CBD Self-Regulation? UK Trade Association Launches Three-Tier Certification System

HBW Insight speaks to the founder of the UK's Association for the Cannabinoid Industry, Steve Moore, about the organization's new three-tier certification system for CBD products marketed in the country, designed to mirror the EU Novel Foods approval process as well as recent local regulatory changes. 

US Firm Mile High Files CBD Novel Food Applications In EU

Colorado's Mile High Labs has filed novel food applications with both EFSA and the UK's FSA to ensure it can keep legally supplying its hemp-derived CBD to European customers.

Related Content

Topics

UsernamePublicRestriction

Register

RS150014

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel